摘要
目的探讨胸腺法新对晚期非小细胞肺癌(NSCLC)患者免疫功能的影响。方法 NSCLC患者100例随机分为2组,治疗组52例,对照组48例,2组均给予联合化疗,治疗组在此基础上加用胸腺法新皮下注射,治疗4个疗程后进行T细胞亚群联合测定,并观察合并感染发生情况。结果(1)免疫功能变化比较:对照组治疗后CD_4^+及CD_8^+变化不明显(P>0.05),CD_4^+/CD_8^+比值降低(P<0.05);治疗组CD_4^+及CD_4^+/CD_8^+升高(P<0.05),CD_8^+变化不明显(P>0.05);治疗组CD_4^+及CD_4^+/CD_8^+高于对照组(P<0.05)。(2)感染发生率比较:治疗组发生感染性疾病16例(30.77%),对照组发生感染性疾病18例(37.50%),2组差异有统计学意义(t=2.021,P<0.05)。(3)生存时间比较:治疗组中位生存时间长于对照组(12.9个月vs.11.9个月,P<0.05)。结论胸腺法新能降低晚期非小细胞肺癌患者的感染发生率,降低因合并感染而发生的病死率,提高患者的中位生存时间。
Objective To investigate the effect of thymalfasin on the immune function of patients with advanced nonsmall cell lung cancer（NSCLC）.Methods 100 NSCLC patients were randomly divided into 2 groups,52 cases in the treatment group,48 cases in the control group,the 2 groups were given combined chemotherapy,the treatment group also used of thymalfasin subcutaneous injection,T cell subsets joint was measured after 4 courses of treatment,and to observe the occurrence of the infection.Results（1） Compared the change of immune function;the control group after treatment,CD4＋ and CD8＋ did not change significantly（P〉 0.05）,CD4＋/CD8＋ ratio decreased（P〈 0.05）,in treatment group,CD4＋ and CD4＋/CD8＋ increased（P〈 0.05）,CD8＋ did not change significandy（P〉0.05）,in the treatment group,CD4＋ and CD4＋/CD8＋higher than that of control group（P〈 0.05）.（2） The incidence of infection;the treatment group had 16 cases of infectious diseases（30.77%）,the control group had 18 cases of infectious diseases（37.50%）,wiu a significant difference between the 2 groups（t =2.021,P 〈0.05）.（3） The survival time;in the treatment group,the median survival time was longer than that of the control group（12.9 months vs.11.9 months,P 〈 0.05）.Conclusion Thymalfasin could reduce the incidence of infection in advanced non-small cell lung cancer patients,as well to reduce mortality due to infection rate,and improve the median survival time of patients.
出处
《疑难病杂志》
CAS
2014年第7期683-685,共3页
Chinese Journal of Difficult and Complicated Cases
关键词
非小细胞肺癌
晚期
胸腺法新
免疫治疗
感染
Non-small cell lung cancer
advanced
Thymalfasin
Immune therapy
Infection
